August 04, 2011
FDA Advises Actos May Increase Bladder Cancer Risk
According to the FDA use of the diabetes medicine Actos for one or more years may be associated with an increased risk of bladder cancer. The information about the risk will be added to the warnings section of the label. The information is from the FDA;s review of data from a planned five year interim analysis of a ten year epidemiological study.
The FDA is also aware of a study done in France which suggested an increased risk of bladder cancer with Actos. Based on their results France has suspended the use of the drug and Germany has recommended no to start any new patients on the drug.
The FDA on August 04, 2011 informed the public that it has approved updated drug labels for the drug Actos to include information that use of Actos for more than one year may be associated with an increased risk of bladder cancer.